cephalosporin c has been researched along with ceftobiprole medocaril in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (39.29) | 29.6817 |
| 2010's | 15 (53.57) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Bento, M; Gjinovci, A; Lew, DP; Li, D; Schrenzel, J; Vaudaux, P | 1 |
| Arias, CA; Murray, BE; Panesso, D; Singh, KV | 1 |
| Amsler, K; Heep, M; Noel, GJ; Pypstra, R; Solomkin, JS; Strauss, RS | 1 |
| Murthy, B; Schmitt-Hoffmann, A | 1 |
| Bagchi, P; Bush, K; Ianus, J; Noel, GJ; Strauss, RS | 1 |
| Moreillon, P | 1 |
| Calhoun, JH; Schmitt-Hoffmann, A; Shapiro, S; Thomas, JK; Yin, LY | 1 |
| Anderson, SD; Gums, JG | 1 |
| Del Pozo, JL; Patel, R | 1 |
| Rybak, MJ; Vidaillac, C | 1 |
| Donskey, CJ; Nerandzic, MM | 1 |
| Acosta, F; Cottagnoud, M; Cottagnoud, P; Egerman, U; Läuffer, J; Stucki, A | 1 |
| Baumgardner, D; Eichenbaum, G; Holsapple, J; Johnson, MD; Ogilvie, B; Parkinson, A; Schmitt-Hoffmann, A; Skibbe, J; Tonelli, F; Usuki, E | 1 |
| Amsler, K; Arbit, D; Balis, D; File, TM; Kaul, P; Michiels, B; Nicholson, SC; Noel, GJ; Strauss, RS; Welte, T | 1 |
| Abbanat, D; Amsler, K; Barron, AM; Fernandez, J; Flamm, RK; Hastings, J; He, W; Lynch, AS; Melton, JL; Queenan, AM; Shang, W | 1 |
| Lagacé-Wiens, PR; Rubinstein, E | 1 |
| Artzi, N; Barnea, Y; Carmeli, Y; Kuzmenko, B; Navon-Venezia, S | 1 |
| Awad, SS; Chuang, YC; Engelhardt, M; Marjanek, Z; Pareigis, AJ; Reis, G; Rodriguez, AH; Sánchez, AS; Saulay, M; Scheeren, TW; Zhou, X | 1 |
| Syed, YY | 1 |
| Scheeren, TW | 1 |
| Guivarch, E; Harpan, A; Montravers, P | 1 |
| Mouton, JW; Pea, F; Torres, A | 1 |
| Almirante, B; Burgos, J; Falcó, V | 1 |
| Azanza Perea, JR; Sádaba Díaz de Rada, B | 1 |
| González-Jiménez, P; Latorre, A; Méndez, R | 1 |
| Hsu, CK; Hsu, WH; Lai, CC | 1 |
15 review(s) available for cephalosporin c and ceftobiprole medocaril
| Article | Year |
|---|---|
Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase III as Topic; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcal Skin Infections; Staphylococcus aureus | 2006 |
Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase III as Topic; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin Resistance; Molecular Structure | 2008 |
New and emerging treatment of Staphylococcus aureus infections in the hospital setting.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase III as Topic; Cross Infection; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Staphylococcal Infections; Staphylococcus aureus | 2008 |
Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials as Topic; Drug Interactions; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2008 |
Ceftobiprole medocaril: a new generation beta-lactam.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Clinical Trials, Phase III as Topic; Humans; Injections, Intravenous; Molecular Structure; Prodrugs | 2008 |
Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Topics: Animals; Cephalosporins; Clinical Trials as Topic; Disease Models, Animal; Drug Interactions; Drug Resistance, Bacterial; Drug Synergism; Humans; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Skin Infections; Time Factors | 2009 |
Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials as Topic; Cross Infection; Dose-Response Relationship, Drug; Humans; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Treatment Outcome | 2013 |
Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Cross Infection; Drug Approval; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Pneumonia, Bacterial; Prodrugs | 2014 |
Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials as Topic; Cross Infection; Drug-Related Side Effects and Adverse Reactions; Enterobacteriaceae; Enterococcus; Europe; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Staphylococcus aureus; Treatment Outcome | 2015 |
Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Humans; Pneumonia, Ventilator-Associated; Risk Factors; Severity of Illness Index | 2016 |
Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations.
Topics: Anti-Bacterial Agents; Area Under Curve; Cephalosporins; Community-Acquired Infections; Critical Illness; Cross Infection; Dose-Response Relationship, Drug; Drug Dosage Calculations; Half-Life; Humans; Infusions, Intravenous; Metabolic Clearance Rate; Microbial Sensitivity Tests; Monte Carlo Method; Pediatrics; Pneumonia; Renal Insufficiency | 2016 |
Ceftobiprole medocaril for the treatment of community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial | 2018 |
Ceftobiprole: pharmacokinetics and PK/PD profile.
Topics: Age Factors; Anti-Bacterial Agents; Area Under Curve; Cephalosporins; Creatinine; Critical Illness; Extracellular Matrix; Half-Life; Humans; Infusions, Intravenous; Kidney; Monte Carlo Method; Obesity; Prodrugs; Renal Insufficiency; Renal Replacement Therapy | 2019 |
Ceftobiprole medocaril.
Topics: Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Humans; Methicillin-Resistant Staphylococcus aureus | 2022 |
Ceftobiprole medocaril for the treatment of pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Child; Gram-Negative Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pneumonia; Staphylococcus aureus; Streptococcus pneumoniae | 2023 |
4 trial(s) available for cephalosporin c and ceftobiprole medocaril
| Article | Year |
|---|---|
Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Female; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Male; Middle Aged; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2008 |
A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
Topics: Aged; Ceftazidime; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2008 |
A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation.
Topics: Acetamides; Adolescent; Adult; Aged; Aged, 80 and over; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Disease Eradication; Double-Blind Method; Drug Therapy, Combination; Female; Hospitalization; Humans; Linezolid; Male; Middle Aged; Oxazolidinones; Pneumonia, Bacterial; Treatment Outcome; Young Adult | 2012 |
A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.
Topics: Acetamides; Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cross Infection; Double-Blind Method; Drug Therapy; Female; Humans; Linezolid; Male; Middle Aged; Oxazolidinones; Pneumonia, Bacterial; Treatment Outcome; Young Adult | 2014 |
9 other study(ies) available for cephalosporin c and ceftobiprole medocaril
| Article | Year |
|---|---|
Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
Topics: Animals; Cephalosporins; Foreign Bodies; Methicillin Resistance; Microbial Sensitivity Tests; Mutation; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2005 |
Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model.
Topics: Ampicillin Resistance; Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Dose-Response Relationship, Drug; Enterococcus faecalis; Gram-Positive Bacterial Infections; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Peritonitis; Vancomycin Resistance | 2007 |
Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus.
Topics: Animals; Body Weight; Cephalosporins; Disease Models, Animal; Methicillin Resistance; Microbial Sensitivity Tests; Osteomyelitis; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Tibia | 2008 |
Effect of ceftobiprole treatment on growth of and toxin production by Clostridium difficile in cecal contents of mice.
Topics: Animals; Anti-Bacterial Agents; Cecum; Cephalosporins; Clostridioides difficile; Female; Mice; Microbial Sensitivity Tests | 2011 |
Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Disease Models, Animal; Escherichia coli; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Haemophilus influenzae; Klebsiella pneumoniae; Meningitis, Bacterial; Microbial Sensitivity Tests; Rabbits; Treatment Outcome | 2012 |
Use of enzyme inhibitors to evaluate the conversion pathways of ester and amide prodrugs: a case study example with the prodrug ceftobiprole medocaril.
Topics: Anti-Bacterial Agents; Aryldialkylphosphatase; Cephalosporins; Enzyme Inhibitors; Esterases; Humans; Hydrolysis; Prodrugs | 2012 |
Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Daptomycin; Drug Dosage Calculations; Drug Synergism; Endocarditis, Bacterial; Female; Humans; Injections, Intravenous; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Rats; Rats, Sprague-Dawley; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2012 |
Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Disease Models, Animal; Male; Mediastinitis; Methicillin-Resistant Staphylococcus aureus; Rats; Staphylococcal Infections; Sternum | 2014 |
Ceftobiprole medocaril (Mabelio). Just another injectable cephalosporin.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Cephalosporins; Humans; Pneumonia, Bacterial | 2015 |